• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi in India – Highlights from 2016

Home > News

DNDi in India – Highlights from 2016

PKDL
21 Mar 2017
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
A group of LF affected older men at a camp in Madhuban Gram Panchayat, Satyavadi Block in Puri district, Odisha, India
A group of lymphatic filariasis affected older men at a camp in Madhuban Gram Panchayat, Satyavadi Block in Puri district, Odisha, India.
Photo credit: Maneesh Agnihotri-DNDi

Identifying unmet patient needs for lymphatic filariasis

In February, the DNDi in India office and the Indian Council of Medical Research organized a clinical experts’ meeting on lymphatic filariasis (LF), bringing together researchers and clinicians from India, Ghana, the US, the Netherlands, and Japan, as well as representatives from WHO, USAID, the Bill & Melinda Gates Foundation, JICA, and the LEPRA Society.

The objective was to identify the unmet needs for the treatment of LF patients in Asia and to define the target product profile (TPP) for LF case management in Asia. After identification of the main gaps in patient case management, two TPPs were drafted, one to treat infected persons (symptomatic or asymptomatic) and the second to stop progression of the disease (probably reverse pathology).

Building alliances against neglected tropical diseases

As India moves toward elimination of key NTDs like LF and visceral leishmaniasis (VL), DNDi in India hosted a meeting of the NTD Platform-Building Alliances against Neglected Tropical Diseases in May. The creation of the Alliance, in February 2016, was spurred by the Global Network for Neglected Tropical Diseases, an international advocacy organization focused on raising the profile of and mobilizing resources for NTDs, and which has helped catalyze coalitions internationally, particularly in donor countries like the UK and Germany.

The Alliance will build on this experience in its function as a platform for all NTD stakeholders in India. One of its first actions was the sending of a community sign-on letter to the Prime Minister’s Office highlighting the importance of keeping NTDs on the BRICS agenda this year as India holds the presidency of the group.

Good Clinical Practice (GCP) training for DNDi partners in Bihar, India
Good Clinical Practice (GCP) training for DNDi partners in Bihar, India

Strengthening clinical research capacity

With the aim of improving the capacity of clinical trial sites and laboratories in conducting research, DNDi in India organized training in Good Clinical Practice and Good Clinical Laboratory Practice at Rajendra Memorial Research Institute (RMRI), Patna, in June 2016, for investigator teams from DNDi, RMRI, Médecins Sans Frontières, Chapra district hospital laboratory, Hajipur district hospital and the National Institute of Pharmaceutical Education and Research.

The objectives of the training were to enable clinical investigators, laboratory technicians, pathologists, nurses and clinical monitors apply the concepts and principles of good clinical practices and international ethical standards in the conduct of clinical trials and observational research, as well as understanding the specificities of clinical trial regulations in India.

Young woman with PKDL.
A young women in Bihar, India with PKDL nodules.
Photo credit: Kishore Pandit-DNDi

New trial to determine cases of PKDL in previously treated leishmaniasis patients

Between 2012 and 2015, DNDi conducted a study to assess the feasibility of using three new treatment regimens to treat visceral leishmaniasis at public health facilities in Bihar, which led the Indian National Kala Azar Elimination Programme to revise its treatment recommendations. Following a request for evidence from the national programme on the occurrence of post-kala-azar dermal leishmaniasis (PKDL) in this large patient cohort, DNDi in India is now seeking to determine the proportion and timing of patients developing PKDL for each of the three new treatment regimens.

All 1761 VL patients treated in the initial study in two districts of Bihar (Patna and Saran/Vaishali) with any of the three new treatment regimens have been invited to participate in the study. At a follow-up visit at least 24-months after VL treatment, participants are assessed for history and clinical manifestation of PKDL. Suspected PKDL cases will be screened with a rapid diagnostic test, and probable PKDL patients referred to the Rajendra Memorial Research Institute for parasitological confirmation.  Patient recruitment is expected to be completed by June 2017, with preliminary reports in late 2017.

How to ensure sustained VL elimination in India?

In November 2016, national and international researchers and operational experts met in New Delhi to launch the SPEAK India consortium. The consortium will aim to develop a post-elimination agenda for visceral leishmaniasis in the Indian subcontinent. Participants worked on defining the research questions to improve our understanding of transmission to inform the post-elimination strategy, and formulated a roadmap to transfer technology on vector biology, disease modelling and diagnostics from international partners.

SPEAK India, funded by the Bill & Melinda Gates Foundation, is a partnership between the Indian Council of Medical Research, the National Vector-Borne Disease Control Programme, the London School of Hygiene and Tropical Medicine, and DNDi.

Partnering with Indian universities to boost open-source drug discovery

In a new open-source drug discovery project called the Open Synthesis Network, DNDi drug discovery projects are brought into academic chemistry teaching labs in a bid to help identify new chemical entities for neglected tropical diseases. DNDi shares its drug discovery data from active projects with academic chemistry departments, and benefits from the synthetic efforts and intellectual design input of students of medicinal chemistry. Participating students get a rare opportunity to observe a real-life drug discovery project in action, and can contribute to the initiative through design and synthesis of target molecules as part of their wet lab training. All data is shared amongst the participating institutions and students in an “open source” environment.

In 2016, DNDi in India office signed a Memorandum of Understanding with two institutes, the Indian Institute of Technology, Gandhinagar and the Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management (NMIMS) to participate in this novel crowdsourcing chemistry student project.

Participants at AMR Meeting in Delhi, India
Participants at AMR Meeting in Delhi, India

Antimicrobial resistance: identifying public health priorities for India

The mission of the Global Antibiotic Research and Development Partnership – a recently launched joint initiative of DNDi and the World Health Organization – is to work with public and private sectors to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which only inadequate treatment exists.

In December 2016, in collaboration with Indian Council of Medical Research, DNDi convened experts and stakeholders in the field of drug-resistant infections in India to advance the understanding of the most pressing medical needs and research and development gaps – including infections and patient groups, national regulations, diagnostics, surveillance factors – and identify strategies to address them. The group also looked at the current Indian landscape in antibiotic R&D and explored collaboration opportunities and ways to capitalize on existing networks.

Drug discovery Strengthening Capacities Cutaneous leishmaniasis Filaria: river blindness Visceral leishmaniasis India

Read, watch, share

Loading...
Davide Paparo and Ian Hausler with their thermotherapy device "CLARA"
Stories
16 Mar 2023

Cutaneous leishmaniasis: Swiss students develop innovative thermotherapy device for safer treatment of ‘flesh-eating parasite’

Stories
8 Mar 2023

Highlighting gender-based treatment gaps on International Women’s Day: Mary Alamak’s story

DNDi-GARDP Southern Africa director, Carol Ruffell (left), presents the December 2022 edition of HIV Nursing Matters and the 2022 paediatric ARV dosing chart to Bénédicte Schutz, Monaco’s Director of International Cooperation (centre), and Yordanos Pasquier, Monaco’s Deputy Director of International Cooperation (right).
News
3 Mar 2023

Working together to ensure optimal treatment for children living with HIV in South Africa

Nurse with patient
Press releases
1 Mar 2023

Fiocruz and DNDi sign strategic alliance agreement

Statements
28 Feb 2023

DNDi’s submission to the Technical Assessment component of the first Global Stocktake

Statements
22 Feb 2023

DNDi comments on the zero draft of the WHO CA+ for consideration of the Intergovernmental Negotiating Body at INB4 & 5

Hat Platform Newsletter N°22 screenshot
Publications
22 Feb 2023

HAT Platform Newsletter No. 22

Lab activities
News
20 Feb 2023

First in-person Dengue Alliance meeting brings together experts from dengue-endemic countries to develop treatments for a growing viral threat

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo